Evolent Health, Inc. (NYSE: EVH) is a Healthcare company (Medical - Healthcare Information Services) with a market capitalization of $520M. The Maz Rating grades it against the other companies in its sector.
Evolent Health, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.62, Evolent Health, Inc. trades at 0.2x sales and 1.4x book value. Over the last twelve months it generated about $2.3B of revenue and a net loss of $500M. It runs a gross margin of 12.1%, an operating margin of -1.0% and a net margin of -21.7%. It shows return on equity of -129.5%, return on invested capital of -1.6% and a free cash flow yield of 5.7%. On the balance sheet: a debt-to-equity ratio of 2.61 and a current ratio of 1.26. Over the past 52 weeks the share price ranged from $2.10 to $6.26, with a beta of 0.84.
Evolent Health, Inc. does not currently pay a dividend.
30 Wall Street analyst ratings cover the stock: 23 Buy and 7 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Evolent Health, Inc., a prominent healthcare firm, operates through its subsidiary, Evolent Health LLC, to furnish clinical and administrative solutions to both healthcare payers and providers across the United States. Its operations are divided into two principal segments: Evolent Health Services and Clinical Solutions. The Evolent Health Services division delivers an integrated platform encompassing both administrative and clinical functions, specifically designed for health plan management and the oversight of population health. This includes essential financial and administrative support, such as managing health plan operations, risk assessment, robust analytics and reporting, and strategic leadership. A cornerstone of this segment is "Identifi," its proprietary technology, which intelligently aggregates and analyzes data, streamlines care workflows, and actively engages patients, all with the aim of achieving patient-centered and cost-effective population health outcomes. Conversely, the Clinical Solutions segment specializes in offering sophisticated care management services for various stakeholders involved in specialty care delivery. These services are crucial for organizations transitioning from traditional fee-for-service models to value-based care, accommodating their unique stage of development and prevailing market dynamics, particularly in the fields of oncology and cardiology. The overarching objective of this segment is a holistic improvement in the total cost of care. Founded in 2011, Evolent Health, Inc. maintains its corporate headquarters in Arlington, Virginia.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Evolent Health, Inc. (EVH) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 199.8% / 30% · (Cash+Inv) / Mkt Cap (36m) 32.3% / 30% · Interest income / Revenue 0.13% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 199.8% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 30.5% / 33% · Receivables / Mkt Cap (36m) 91.2% / 49% · Interest income / Revenue 0.13% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 199.8% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 30.5% / 33.33% · Receivables / Mkt Cap (24m) 91.2% / 33.33% · Interest income / Revenue 0.13% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 50.4% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 7.54% / 33.33% · Receivables / Avg Assets (4Q) 19.8% / 33.33% · Interest income / Revenue 0.13% / 5% | Fail |
| FTSE | Debt / Total Assets 49.4% / 33.33% · (Cash+ST Inv) / Total Assets 7.56% / 33.33% · (Cash+Recv) / Total Assets 30.1% / 33.33% · Interest income / Revenue 0.13% / 5% | Fail |
No. As of September 2026, Evolent Health, Inc. (EVH) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Evolent Health, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m) and (Cash+Inv) / Mkt Cap (36m).
About 0.13% of each dividend: Evolent Health, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.